Paclitaxel, Not Bevacizumab, Was Primarily Responsible for the Favorable Effects Seen in the RIBBON-2 Trial


Kesikli A., KILIÇKAP S.

JOURNAL OF CLINICAL ONCOLOGY, vol.30, no.4, pp.461, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 30 Issue: 4
  • Publication Date: 2012
  • Doi Number: 10.1200/jco.2011.40.2305
  • Title of Journal : JOURNAL OF CLINICAL ONCOLOGY
  • Page Numbers: pp.461